An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
Study Warns: AI Alone Is Not Enough in Critical Healthcare Decisions
Evaluating both AI algorithms and human users is key for safe adoption in high-stakes healthcare settings, according to an Ohio State study.
•EurekAlert
AI Dramatically Improves Prediction of Delivery Timing from Ultrasound Images
Ultrasound AI's study validates advanced AI for predicting delivery timing using standard ultrasound images.
•EurekAlert
AI-Assisted Colonoscopies May Reduce Clinicians’ Detection Skills, Study Finds
Routine use of AI in colonoscopies linked to decreased skill in adenoma detection by clinicians without AI assistance.